All News

At NAACOS 2026, value-based care leaders make the case for treating payers as partners and explain what providers must see in return.

A lengthy Ways and Means Committee hearing revealed extensive Medicare system exploitation and ignited partisan debates on fixing it.

Speakers at the NAACOS Spring 2026 Conference illustrated means of using technology in value-based care to implement preventive medicine.

New reports spotlight inequities—from Black maternal mortality to 988’s youth impact—as well as rising cancer risk and gaps in food aid.

Explore 5 FAQs on CDC opioid guidelines, including dosing, tapering, monitoring, and managed care strategies to reduce overdose risk.

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

Bispecific antibodies are delivering unprecedented response rates in multiple myeloma, offering fast, flexible options alongside CAR T-cell therapy, explains Prerna Mewawalla, MD.

Pediatric care deserts push Medicaid families into costly ED visits; learn how primary care access gaps fuel chronic issues and spending.

Mosunetuzumab, a bispecific, plus polatuzumab vedotin, an antibody-drug conjugate, deliver high response rates in relapsed MCL, potentially enabling outpatient community oncology treatment and wider patient access.

FDA grants lunsotogene parvec-cwha approval for OTOF-related hearing loss, delivering single-dose gene therapy gains and expanding access with free US supply.

Off-the-shelf cema-cel clears MRD at more than triple the rate of observation alone—and may propel a shift to frontline use of CAR T-cell therapy when relapse is hard to detect.

The DEA's 30th biannual collection event arrives April 25, 2026—here's what patients and clinicians need to know.

The FDA approved dupilumab for children aged 2 to 11 years with uncontrolled CSU—the first biologic for this pediatric population.

Nicole A. Caffiero, PharmD, MBA, BCACP, concluded AMCP 2026 by highlighting key themes shaping the specialty drug market.

Parth Desai, MBBS, MD, discusses how clinicians balance liquid biopsy, tissue testing, and fast-start chemo to personalize non–small cell lung cancer treatment.

Cemdisiran offers lower treatment burden for patients living with generalized myasthenia gravis, only needing to be taken every 3 months.

An analysis shows accelerated declines in processing speed, memory, and global cognition years before incident cardiovascular disease.

The Merit-Based Incentive Payment System (MIPS) measure excluded nearly half of all patients undergoing surgery, which could affect surgeon performance.

FDA approves doravirine/islatravir, a once-daily, 2-drug, single-tablet HIV regimen showing noninferior efficacy to standard therapies in suppressed adults.

Teplizumab-mzwv is the first disease-modifying therapy available for children as young as 1 year diagnosed with presymptomatic type 1 diabetes.

OUD diagnoses have declined, but use of medication to treat OUD has increased among Medicaid beneficiaries, highlighting policy gains and ongoing state-level disparities.

988 Lifeline rollout linked to 11% drop in youth suicide deaths, with greater reductions in states with higher call uptake, study finds.

PFAS exposure, especially PFDA, was linked to higher nonmelanoma skin cancer odds, with stronger effects observed in older adults.

There was comparable 12-month fitness and functional outcomes in lymphoma survivors, suggesting a scalable option to expand access to cardio-oncology care.

Young-onset CRC mortality rose over 3 decades in the US, largely among adults with lower educational attainment, widening socioeconomic gaps.

A new AHIP report outlines evidence-based strategies to cut chronic disease prevalence by 10% by 2035.

The 5-year prediction of MS progression, defined by clinical and objective measurements, was possible with 2 machine learning tools.

Black Maternal Health Week spotlights disparities, Medicaid postpartum coverage gains, and ongoing policy efforts to reduce maternal mortality.